Business
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD,
About this update from Dyne Therapeutics, Inc.
[{"type":"text","content":"- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointments of Vikram (Vik) Ranade, PhD, as chief business officer (CBO) and Ranjan (Ron) Batra, PhD, as chief scientific officer (CSO) of Dyne. Dr. Ranade will lead business development, corporate strategy and strategic partnerships to support the company’s late-stage clinical and commercialization plans. Dr. Batra will lead the company’s research strategy, pipeline development and activities supporting clinical development. Effective April 28, 2025, Oxana Beskrovnaya, PhD, will transition from CSO to chief innovation officer (CIO) responsible for driving Dyne’s comprehensive innovation strategy to maximize the value of its FORCE™ platform and further enable the company’s long-term success. “I am excited to welcome Vik and Ron to our leadership team. Vik’s experience in business development and corporate strategy will be invaluable as we prepare for the potential launches of two medicines in 2027 in myotonic dystrophy type 1 and Duchenne muscular dystrophy. Our incoming CSO, Ron, will play a key role in advancing our pipeline and elucidating the power of the FORCE platform to deliver functional improvement in the clinic,” said John Cox, president and chief executive officer of Dyne. “With the addition of Vik, Ron and our CFO, Erick Lucera, as well as Oxana in her new role as CIO, we are well positioned to drive the business, deliver therapies that bring functional improvement to patients and create significant shareholder value through our clinical programs, pipeline and unique platform.” Dr. Ranade joins Dyne, effective immediately, from Tessera Therapeutics, where he was senior vice president of corporate development, leading strategy and business development, and was member of the executive team. During more than five years at Tessera he also played a key role in equity financings totaling more than $600 million. Previously, he worked in McKinsey & Company’s healthcare practice, advising ...